04:51 PM EDT, 08/08/2024 (MT Newswires) -- Xenon Pharmaceuticals ( XENE ) reported a Q2 net loss late Thursday of $0.75 per diluted share, compared with a loss of $0.72 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.71.

The company didn't record revenue in the quarter that ended June 30 or a year earlier. Analyst estimates were not available for comparison.

Xenon said it ended the quarter with cash and cash equivalents and marketable securities of $850.6 million, sufficient to fund operations into 2027.